Fentanyl Analogs Other Synthetic Opioids

Total Page:16

File Type:pdf, Size:1020Kb

Fentanyl Analogs Other Synthetic Opioids Opioid-Involved Fatal Overdoses and the Role of Higher Dosage Strength Opioid Products: What We Do and Don’t Know Bruce A. Goldberger, Ph.D. Division of Forensic Medicine Department of Pathology, Immunology and Lab Medicine University of Florida College of Medicine 1 What is there that is not poison? All things are poison and nothing is without poison. Solely the dose determines that a thing is not a poison. – Paracelsus (1493-1541) A poison in a small dose is a medicine, and a medicine in a large dose is a poison. – Alfred Swaine Taylor (1859) 2 3 4 5 Medicolegal Death Investigation – Drugs in Decedents − Volatiles − Over-the-Counter Drugs − Prescription Drugs − Illicit Drugs 6 Opioids Benzodiazepines • Buprenorphine • Alprazolam • Codeine • Clonazepam • Fentanyl • Diazepam • Hydrocodone • Lorazepam • Temazepam • Hydromorphone • Methadone Stimulants • Morphine • Amphetamines • Oxycodone • Cocaine • Oxymorphone • Tapentadol • Tramadol 7 Illicit Drugs and NPS − Cannabis, cocaine, heroin, methamphetamine and phencyclidine − New psychoactive substances (NPS) including aminoindanes; synthetic cannabinoids; synthetic cathinones; phenethylamines; piperazines; plant- based substances; tryptamines; other substances 8 Synthetic Opioids FENTANYL ANALOGS OTHER SYNTHETIC OPIOIDS Acetylfentanyl AH-7921 Acrylfentanyl MT-45 4-ANPP U-47700 Butyrylfentanyl U-49900 Carfentanil U-50488 ortho-Fluorofentanyl para-Fluorobutyryl fentanyl para-Fluorofentanyl Furanylfentanyl Isobutyrylfentanyl Methoxyacetylfentanyl 4-Methoxybutyrylfentanyl 4-Methylphenethylacetylfentanyl 3-Methylfentanyl Beta-hydroxythiofentanyl Valerylfentanyl 9 Polysubstance Use − Fatal intoxication is common amongst prescription and illicit drug users − Number of drugs ingested is directly related to incidence of fatal overdose − Fatal overdoses include accidental and intentional overdose 10 Common Opioid Drug-Drug Combinations − Opioids + Alcohol − Opioids + Benzodiazepines − Fentanyl/Fentanyl Analog + Cocaine − Fentanyl/Fentanyl Analog + Methamphetamine 11 Toxicological Considerations − Predominant drug effect • depressant and stimulant − Combined drug effect • additive and synergistic − Frequency of drug administration • acute and chronic (tolerance) − Use of an antagonist 12 Polysubstance Use Among Drug- Caused Deaths in Florida (2017) In Combination with Drug Deaths Most Common Other Drugs (excluding metabolite) Cocaine 2012 88.2% Fentanyl Fentanyl 1743 92.8% Cocaine Fentanyl Analogs 1588 91.6% Cocaine Morphine 1285 97.8% Cocaine Heroin 944 99.0% Cocaine Alprazolam 791 97.7% Cocaine Oxycodone 610 95.2% Alprazolam Methamphetamine 464 95.7% Fentanyl Methadone 247 91.5% Alprazolam Hydrocodone 226 95.1% Alprazolam Diazepam 178 98.9% Morphine Tramadol 102 90.2% Alprazolam Carisoprodol 23 100.0% Oxycodone Florida Drug-Related Outcomes Surveillance and Tracking System (FROST), 2019 13 − CNS depression with loss of consciousness − Respiratory depression and apnea − Miosis 14 The ME/C should correlate the constellation of signs and symptoms associated with the ingestion of a specific drug or drug class. 15 − Pulmonary edema and hyperemia − Bronchopneumonia − Cerebral edema − Congestion in liver and other organs − Retention of urine − Other pathology including cardiomyopathy and coronary artery disease 16 − Potency of drug and consideration of drug- drug interaction(s) − Significance of autopsy and toxicological findings − Interaction of natural disease and drugs − Consideration of MDI findings 17 MDI Utilization of the PDMP — Establish prescription drug use history — Compare PDMP data with decedent’s medication inventory from scene — Evaluate evidence of drug use – with and without a prescription — Identify health care providers from whom the decedent's medical history can be obtained — Assess likelihood for tolerance to psychoactive drugs including benzodiazepines and opioids — Establish the role of drugs in a drug intoxication death — Identify drug treatment programs, if these data are available in the jurisdiction Adapted from Uniform Standards and Case Definitions for Classifying Opioid-Related Deaths: Recommendations by a SAMHSA Consensus Panel – Goldberger et al., J Addict Dis. 2013 Jul; 32(3): 231–243. 18 Fentanyl-Caused Deaths and Fentanyl Rx in Florida 80 40 70 35 Thousands 60 30 50 25 40 20 Deaths, No. 30 15 Prescriptions, No. Prescriptions, 20 10 10 5 0 0 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Fentanyl (Death) Fentanyl (Rx) 19 Surveillance Opportunities: Time 160 450 PDMP Implementation 140 400 Thousands 350 120 300 100 250 80 200 Deaths, No. Deaths, 60 150 No. Prescriptions, 40 100 20 50 0 0 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Alprazolam (Deaths) Oxycodone (Deaths) Alprazolam (Rx) Oxycodone Long Acting (Rx) Oxycodone Short Acting (Rx) 20 Unadjusted death rates for drug overdose by benzodiazepine prescription history and daily opioid dose. Tae Woo Park et al. BMJ 2015;350:bmj.h2698 21 ©2015 by British Medical Journal Publishing Group BMJ 2018;362:k3207 23 MMWR / November 4, 2011 / Vol. 60 / No. 43 In conclusion, we found that a higher daily dose of opioids is associated with large relative and absolute increases in opioid-related mortality, and that daily doses of 200 mg or more of morphine (or equivalent) are associated with a particularly high risk. Our findings have important implications, largely because most opioid- related deaths were avoidable and occurred in young people. We believe physicians should carefully assess the appropriateness of long-term use of opioids to treat chronic, noncancer-related pain, particularly at high doses. 24 Arch Intern Med. 2011;171(7):686-691 Figure 4 Incidence rates and incidence rate ratios for overdose deaths involving opioid analgesics, by average daily ... 25 Figure 5 Incidence rate ratios for overdose deaths involving opioid analgesics, by benzodiazepine prescription status. ... 26 27.
Recommended publications
  • A Review of Synthetic Fentanyl Metabolism and the Metabolism of Select Synthetic Fentanyl Analogues
    A review of synthetic fentanyl metabolism and the metabolism of select synthetic fentanyl analogues Gerard Lee A thesis submitted for the completion of a degree in Master of Forensic Science (Professional Practice) in The School of Veterinary and Life Sciences Murdoch University Supervisors: Associate Professor James Speers (Murdoch) Associate Professor Bob Mead (Murdoch) Semester 1, 2019 i Declaration I declare that this thesis does not contain any material submitted previously for the award of any other degree or diploma at any university or other tertiary institution. Furthermore, to the best of my knowledge, it does not contain any material previously published or written by another individual, except where due reference has been made in the text. Finally, I declare that all reported experimentations performed in this research were carried out by myself, except that any contribution by others, with whom I have worked is explicitly acknowledged. ii Acknowledgements I would like to thank my supervisor Bob Mead for his time guiding me and providing feedback on this endeavour. He has been a great help providing insights and advice from when I started university at Murdoch until now for which I am extremely grateful. To James Speers, thank you for helping me find a direction for this project when I started out. And finally, to my family and friends for their encouragement and support. iii Table of Contents Title page. ...............................................................................................................................I
    [Show full text]
  • 18 December 2020 – to Date)
    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
    [Show full text]
  • 2015-02 Toxicology Rapid Testing Panel
    SOUTH CAROLINA LAW ENFORCEMENT DIVISION NIKKI R. HALEY MARK A. KEEL Governor Chief FORENSIC SERVICES LABORATORY CUSTOMER NOTICE 2015-02 REGARDING TOXICOLOGY RAPID TESTING PANEL August 12, 2015 This notice is to inform the Coroners of South Carolina of a new testing panel available through the SLED Toxicology Department. On Monday, August 17th, the Toxicology Department will begin offering both a Rapid Testing Panel in addition to the already available Expanded Testing Panel. This Rapid Testing Panel is to be utilized in cases where the Expanded Testing Panel is not warranted, specifically where a cause of death has already been established. The Rapid Testing Panel will consist of volatiles analysis, to include, ethanol, acetone, isopropanol and methanol, drug screens, and drug confirmation/quantitation of positive screens. The cases assigned to the Rapid Testing Panel will have an expedited turnaround time. Targeted turn around times will be two weeks for negative cases and six weeks or less for positive cases. While every effort will be made to adhere to these time frames, additional time may be required on occasion due to the nature of postmortem samples. Submitters will be notified if there is a problem with a particular sample. Please see attachment regarding specifically which substances are covered by the Rapid Testing Panel and the Expanded Testing Panel. As always, a detailed case history and list of drugs suspected is appreciated. Rapid Panel and Expanded Panel will be choices available in iLAB. Please contact Lt. Dustin Smith (803-896-7385) with additional questions. ALI-359-T An Accredited Law Enforcement Agency P.O.
    [Show full text]
  • Food and Drug Administration 5630 Fishers Lane, Rm
    Sent via Electronic and U.S. Mail October 13, 2015 James R. Hunter Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2015-N-0045 for International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; Ketamine; Phenazepam; Etizolam; 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine (MT-45); N-(1-Phenethylpiperidin- 4-yl)-N-phenylacetamide (Acetylfentanyl); α-Pyrrolidinovalerophenone (α-PVP); 4- Fluoroamphetamine (4-FA); para-Methyl-4-methylaminorex (4,4’-DMAR); para- Methoxymethylamphetamine (PMMA); 2-(ethylamino)-2-(3-methoxyphenyl)- cyclohexanone (Methoxetamine or MXE); Request for Comments Dear Mr. Hunter: This letter responds to the Food and Drug Administration’s (FDA) request for comments that appeared in the Federal Register on October 5, 2015, concerning International Drug Scheduling. The Association of Public and Land-grant Universities (APLU) represents 237 public research universities, land-grant institutions, state university systems, and affiliated organizations. Many of our member institutions have veterinary and medical schools and nearly all our institutions have researchers and students who conduct biomedical research. On behalf of our institutional membership, APLU appreciates this opportunity to provide the FDA with comments. APLU strongly objects to any attempt to alter the international regulation of ketamine that would result in increased difficulty for biomedical researchers to use this drug for legitimate and appropriate treatments. The United States currently classifies ketamine as a Schedule III drug under the Controlled Substance Act (CSA). As such, strict regulations and safeguards are already in place to prevent its illegal use. As known to FDA, Schedule I drugs are defined as those with no currently acceptable medical use, a lack of accepted safety for use under medical supervision, and a high potential for abuse.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • Understanding and Challenging the Drugs: Chemistry and Toxicology
    UNDERSTANDING AND CHALLENGING THE DRUGS: CHEMISTRY AND TOXICOLOGY Presenter: • Dr. Jasmine Drake, Graduate Program Director and Assistant Professor, Administration of Justice Department, Barbara Jordan-Mickey Leland School of Public Affairs, Texas Southern University NACDL Training Defending Drug Overdose Homicides in Pennsylvania Penn State Harrisburg, Middletown, PA November 6th, 2019 11:30- 12:45 p.m. Understanding & Challenging the Drugs: Chemistry & Toxicology Dr. Jasmine Drake, Forensic Science Learning Laboratory, Texas Southern University I. Opioid Drug Classifications A. Types of Opioids B. Classic vs. Synthetic C. Toxicology of Opioids 1) How opioids interact with the body 2) Addiction (psychological vs. physiological II. New Classes of Drugs A. Emerging Threats B. Potency III. National Trends in Opioid Overdose Deaths in the U.S. A. Based on State B. Ethnicity C. Drug-Type (prescription vs. fentanyl vs. heroin) IV. Trends of Opioid Overdose Deaths in Philadelphia A. Based on Ethnicity B. Drug Type (prescription vs. fentanyl vs. heroin) V. Legal Considerations to the Opioid Epidemic A. Punitive Measures vs. Rehabilitative Treatment B. Progressive Jurisdictions Nationwide C. New Legal Measures in Philadelphia VI. Toxicology Reports A. What’s in the report? B. Key Aspects of the Tox Report C. Terminology D. Evaluating and Interpreting the data? E. Questions and considerations. VII. Conclusion and Discussion A. Case Specific Examples B. Sample Toxicology Reports The Opioid Epidemic: What labs have to do with it? Ewa King, Ph.D. Associate Director of Health RIDOH State Health Laboratories Analysis. Answers. Action. www.aphl.org Overview • Overdose trends • Opioids and their effects • Analytical testing approaches • Toxicology laboratories Analysis. Answers. Action.
    [Show full text]
  • Safety Notice 009/20 Acetylfentanyl and Fentanyl In
    Safety Notice 009/20 Acetylfentanyl and fentanyl in non-opioid illicit drugs 16 October 2020 Background Distributed to: A cluster of hospitalisations due to unexpected opioid toxicity recently occured on • Chief Executives the Central Coast of NSW. Acetylfentanyl and fentanyl are circulating in NSW and • Directors of Clinical Governance may be misrepresented as or be adulterants in illicit cocaine or ketamine. • Director Regulation and Acetylfentanyl has a similar potency to fentanyl, both may cause serious harm and Compliance Unit death. People who do not use opioids regularly (‘opioid naïve’) may be unintentionally exposed and are at high risk of overdose. Even people who Action required by: regularly use opioids are at risk due to the relatively high potency of fentanyl and • Chief Executives acetylfentanyl. • Directors of Clinical Changes in illicit drug use in 2020, as well as variations in purity and alternative Governance ingredients, may be associated with unusual presentations and overdose. • Director Regulation and Compliance Unit Case management • We recommend you also Have a high index of suspicion for illicit fentanyl and fentanyl analogues in inform: suspected opioid overdose. This includes people who deny opioid use or • Drug and Alcohol Directors report use of other non-opioid illicit drugs including ketamine or stimulants and staff such as cocaine, but who present clinically with signs of an opioid • All Service Directors overdose. • Emergency Department • Intensive Care Unit • Airway management, oxygenation, and ventilation support take precedence • Toxicology Units over naloxone, where appropriate. • Ambulance • Cases may require titrated doses of naloxone with a higher total dose of • All Toxicology Staff 800 micrograms or more.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • UCSF UC San Francisco Previously Published Works
    UCSF UC San Francisco Previously Published Works Title Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review Permalink https://escholarship.org/uc/item/8xh0s7nf Authors Armenian, Patil Vo, Kathy Barr-Walker, Jill et al. Publication Date 2017-10-01 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review Patil Armenian, Kathy Vo, Jill Barr-Walker, Kara Lynch University of California, San Francisco-Fresno and University of California, San Francisco Keywords: opioid, synthetic opioids, fentanyl, fentanyl analog, carfentanil, naloxone Abbreviations: 4-ANPP: 4-anilino-N-phenethyl-4-piperidine; ANPP 4Cl-iBF: 4-chloroisobutyryfentanyl 4F-iBF: 4-fluoroisobutyrfentanyl AEI: Advanced electronic information AMF: alpha-methylfentanyl CBP: US Customs and Border Protection CDC: Centers for Disease Control CDSA: Controlled Drug and Substance Act (Canada) CNS: central nervous system DEA: US Drug Enforcement Agency DTO: Drug trafficking organization ED: Emergency department ELISA: enzyme-linked immunosorbent assay EMCDDA: European Monitoring Centre for Drug and Drug Addiction FDA: US Food and Drug Administration GC-MS: gas chromatography mass spectrometry ICU: intensive care unit IN: intranasal IV: intravenous LC-HRMS: liquid chromatography high resolution mass spectrometry LC-MS/MS: liquid chromatography tandem mass spectrometry MDA: United Kingdom Misuse of Drugs Act NPF: non-pharmaceutical fentanyl THF-F: tetrahydrofuranfentanyl US: United States USPS: US Postal Service UNODC: United Nations office on drugs and crime 1. Introduction The death rate due to opioid analgesics nearly quadrupled in the US from 1999 to 2011 and was responsible for 33,091 deaths in 2015 (CDC, 2014; Rudd et al., 2016).
    [Show full text]
  • EU EARLY WARNING SYSTEM ADVISORY Fake Oxycodone Tablets
    EU EARLY WARNING SYSTEM ADVISORY Fake oxycodone tablets containing brorphine — Slovenia, 2021 RCS ID: EU-EWS-RCS-AD-2021-0001 Issued by: EMCDDA Date issued: 22/01/2021 Transmitted by: Action on New Drugs Sector, EMCDDA Recipients: Early Warning System Network Read with: EU-EWS-RCS-FN-2020-0013 1. Summary and purpose Brorphine is a synthetic opioid monitored by the EMCDDA as a new psychoactive substance. It has been available in Europe since at least March 2020. Its identification has been reported by 4 countries: Belgium, Germany, Slovenia, and Sweden. Similar to other new opioids, brorphine is sold as a replacement to controlled opioids on the surface web, darknet markets, and at street-level. The available information suggests that, similar to fentanyl, brorphine is a potent opioid. Overdose may cause life-threatening poisoning from respiratory depression and arrest. Deaths involving brorphine have been reported in the United States (20 deaths). The purpose of this advisory is to: Highlight a recent identification of two fake oxycodone tablets containing brorphine in Slovenia that were sold on the internet as oxycodone. Highlight that brorphine appears to be a potent opioid that may pose a high risk of life-threatening poisoning. Deaths have been reported in the United States. Request that you report any information you have on brorphine to the EMCDDA as soon as possible so that we can improve our understanding of the potential risks. Information should be reported by email to [email protected] 2. Advisory Background EU-EWS-RCS-AD-2021-0001 Page 1 of 6 Brorphine is a synthetic opioid monitored by the EMCDDA as a new psychoactive substance [1].
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2021 (July Update)
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2021 (July update) Afghanistan Bezitramide 1 Codeine 20 000 Cannabis 7 050 Dextropropoxyphene 20 000 Cannabis resin 1 Diphenoxylate 800 Coca leaf 1 Fentanyl 6 Cocaine 15 Methadone 120 000 Codeine 700 000 Morphine 10 000 Codeine-N-oxide 1 Pethidine 2 000 Dextromoramide 1 Pholcodine 5 000 Dextropropoxyphene 170 000 Albania Difenoxin 1 Cocaine 1 Dihydrocodeine 1 Codeine 1 190 000 Diphenoxylate 1 Fentanyl 300 Dipipanone 1 Heroin 1 Ecgonine 2 Methadone 16 500 Ethylmorphine 1 Morphine 7 500 Etorphine 1 Oxycodone 1 500 Fentanyl 17 200 Pethidine 2 500 Heroin 1 Pholcodine 1 600 Hydrocodone 11 000 Remifentanil 10 Hydromorphone 4 000 Sufentanil 2 Ketobemidone 1 Algeria Levorphanol 1 Alfentanil 400 Methadone 110 000 Cannabis 3 Morphine 1 590 000 Cocaine 5 Morphine-N-oxide 1 Codeine 2 500 000 Nicomorphine 1 Etorphine 1 Norcodeine 1 Fentanyl 900 Normethadone 1 Heroin 2 Normorphine 1 Methadone 4 000 Opium 10 Morphine 15 000 Oripavine 1 Oxycodone 4 000 Oxycodone 60 000 Pethidine 3 000 Oxymorphone 1 Pholcodine 1 500 000 Pethidine 50 000 Remifentanil 1 Phenoperidine 1 Sufentanil 50 Pholcodine 1 Andorra Piritramide 1 Cannabis 2 000 Remifentanil 17 000 Fentanyl 100 Sufentanil 10 Methadone 1 000 Thebacon 1 Morphine 500 Thebaine 77 000 Oxycodone 2 000 Tilidine 1 Pethidine 500 Armenia Remifentanil 4 Codeine 3 000 Angola Fentanyl 50 Alfentanil 24 Methadone 22 000 Codeine 21 600 Morphine 8 000 Dextromoramide 188 Thebaine 4 100 Dextropropoxyphene 200 Trimeperidine 1 500 Dihydrocodeine 500 Aruba* Diphenoxylate
    [Show full text]
  • Comprehensive Multi-Analytical Screening Of
    COMPREHENSIVE MULTI-ANALYTICAL SCREENING OF DRUGS OF ABUSE, INCLUDING NEW PSYCHOACTIVE SUBSTANCES, IN URINE WITH BIOCHIP ARRAYS APPLIED TO THE EVIDENCE ANALYSER Darragh J., Keery L., Keenan R., Stevenson C., Norney G., Benchikh M.E., Rodríguez M.L., McConnell R. I., FitzGerald S.P. Randox Toxicology Ltd., Crumlin, United Kingdom e-mail: [email protected] Introduction Biochip array technology allows the simultaneous detection of multiple drugs from a single undivided sample, which This study summarises the analytical performance of three different biochip arrays applied to the screening of increases the screening capacity and the result output per sample. Polydrug consumption can be detected and by acetylfentanyl, AH-7921, amphetamine, barbiturates, benzodiazepines (including etizolam and clonazepam), incorporating new immunoassays on the biochip surface, this technology has the capacity to adapt to the new trends benzoylecgonine/cocaine, benzylpiperazines, buprenorphine, cannabinoids, carfentanil, dextromethorphan, fentanyl, in the drug market. furanylfentanyl, meprobamate, mescaline, methamphetamine, methadone, mitragynine, MT-45, naloxone, ocfentanyl, opioids, opiates, oxycodone, phencyclidine, phenylpiperazines, salvinorin, sufentanil, synthetic cannabinoids (JWH-018, UR-144, AB-PINACA, AB-CHMINACA), synthetic cathinones [mephedrone, methcathinone, alpha- pyrrolidinopentiophenone (alpha-PVP)], tramadol, tricyclic antidepressants, U-47700, W-19, zolpidem. Methodology Three different biochip arrays were used (DOA ULTRA,
    [Show full text]